Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1990-12-07
1994-02-15
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Lymphokine
424 852, 514 2, 514 8, 514 21, A61K 3702, C07K 1506
Patent
active
052864820
ABSTRACT:
The present disclosure relates to a new lymphokine molecule, referred to as Monocyte Cytotoxicity Inducing Factor (MCF), and its use as in cancer and other types of therapy. The disclosure further relates to the development of novel Sezary cell hybridomas which secrete MCF and thereby provide a ready source for MCF isolation and purification.
Sezary's Syndrome is a leukemic proliferation of OKT4+ lymphocytes. Sezary cells were isolated by differential centrifugation and fused to CEM.8aza.sup.r/. C, an HGPRTase lacking clone of CEM. The hybrid cells were studied for their ability to produce soluble mediators of human monocyte cytotoxicity. The product of a single clone, FtF3, which bore the surface phenotype of Sezary cells, was characterized. Monocyte cytotoxicity inducing factor was found to be stable at pH 2 for one hour, unlike interferon-gamma, and was found to be more heat stable as well. Moreover, treatment of MCF with antisera to interferons gamma, alpha, or a combination of gamma and alpha failed to neutralize its biologic activity.
MCF binds to Matrex Gel Red A. MCF eluted-from this dye-ligand was found to have an apparent molecular weight of 11,500 Daltons by gel filtration and 14,700 Daltons by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
A molecular weight of 29,000 daltons was found by use of SDS-PAGE in a second species of MCF produced under serum-free conditions.
REFERENCES:
patent: 472998 (1988-02-01), Cantor et al.
patent: 4977245 (1990-12-01), Jones
patent: 5112948 (1992-05-01), Jones
Yoshida et al. (1975), Jrnl. Immunol., 114:915-918.
Broder et al. (1976), Jrnl. Clin. Invest., 58:1297-1306.
Cohn (1978), Jrnl. Immunol., 121:813-816.
Gmelig-Meyling (1980), Jrnl. Immunol. Meth., 33:1-9.
Wiltrout et al. (1981) in Manual of Macrophage Methodology, Marcel Dekker, Inc. p. 337-344.
Okada et al. (1981), P.N.A.S., 78:7717-1721.
Fischer et al. (1981), Cell. Immunol., 58:426-435.
Jones et al. (1981), Nature, 251:302-303.
Ralph et al. (1982), Cell. Immunol., 71:215 Biosis Abstract 76042709.
Le et al. (1983), J. Immunol., 131:2821 Index Medicus Abstract
Celada et al. (1984), J. Exp. Med., 160:55 (Abstract).
Eyster et al. (1983), N.E.J.M., 309:583-586.
Jones et al. (1984), Immunobiol., 167; Abstract No. 365.
Nathan et al. (1984), J. Exp. Med., 160:600-605.
Kleinerman et al. (1985), Cancer Res., 45:2058 (Abstract only).
Sadlik et al. (1985), Cancer Res., 45:1940 (Abstract only).
Proust et al. (1985), J. Immunol., 134:390 (Abstract only).
Jones et al. (1984), Immunobiol., 166:410-427.
Grillot-Courvalin et al. (1985) in T. Cell Hybridomas, CRC Press, pp. 223-224.
Grabstein et al. (1986), Science, 232:506 (Abstract only).
Jones et al. (1986) J. Immunol, 137:571-577.
Daemen et al. (1986), Cancer Res., 46:4330-4335.
Rosenberg et al. (1986) Science, 233:1318-1321.
Goldstein et al. (1980), Cancer Res., 46:4315-4329.
Jones et al. (1988), Immunobiol., 178:229-249.
Meltzer, et al., (1982) Fed. Proc. 41:2198-2205.
Matthews, N. (1985) Eur. J. Immunol., 15:311-313.
Gregory et al. Biosis Abstract 83:34188 of J. Immunol. 137 pp. 3231-3239 (1986).
Board of Regents , The University of Texas System
Russel Jeffrey E.
LandOfFree
Methods and compositions for inducing monocyte cytotoxicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inducing monocyte cytotoxicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inducing monocyte cytotoxicity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1205018